Genentech, Biogen ask FDA to broaden Rituxan use

Genentech and partner Biogen Idec are asking the FDA to allow their cancer drug Rituxan to be used in combination with chemotherapy for people with chronic lymphocytic leukemia. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.